Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR | Q13258 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | RARB | P10826 | 5/20 | 0.38 |
| ▸ | RARG | P13631 | 5/20 | 0.38 |
| ▸ | RARA | P10276 | 4/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
| ▸ | HNF4A | P41235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17847413 | 0.79 | PTGDR (0.44) | PTGDRPTGDR2RARBRARGRARA | |
| SCHEMBL19639459 | 0.76 | PTGDR (0.44) | PTGDRPTGDR2RARBRARGRARA | |
| SCHEMBL17847398 | 0.75 | PTGDR2 (0.43) | PTGDRPTGDR2RARBRARGRARA | |
| SCHEMBL23927772 | 0.73 | PTGDR (0.39) | PTGDRPTGDR2ALDH1A1 | |
| SCHEMBL17847402 | 0.73 | THRA (0.37) | PTGDR2RARBRARGRARAALDH1A1 | |
| SCHEMBL19639458 | 0.72 | PTGDR (0.39) | PTGDRPTGDR2ALDH1A1 | |
| SCHEMBL17847377 | 0.71 | RARB (0.49) | PTGDRPTGDR2RARBRARGRARA | |
| SCHEMBL3181105 | 0.67 | POLB (0.50) | APOBEC3GALDH1A1 | |
| SCHEMBL2225715 | 0.64 | RARB (0.51) | RARBRARGRARAALDH1A1RXRA | |
| SCHEMBL20116603 | 0.64 | TSHR (0.60) | APOBEC3GALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107250115-B | Compounds, synthesis method thereof and application thereof in medicines and cosmetics | 盖尔德马研究及发展公司 | 2021-11-05 | — | — | CN | disclosed |
| EP-3233806-B1 | HETEROCYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS | GALDERMA RES & DEV (FR) | 2021-10-27 | — | — | EP | disclosed |
| US-10647688-B2 | Compounds, synthesis method thereof and use of same in medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2020-05-12 | — | — | US | disclosed |
| US-20170342040-A1 | NOVEL COMPOUNDS, SYNTHESIS METHOD THEREOF AND USE OF SAME IN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-11-30 | — | — | US | disclosed |
| EP-3233806-A1 | NOVEL COMPOUNDS, SYNTHESIS METHOD THEREOF AND USE OF SAME IN MEDICINE AND IN COSMETICS | Galderma Research & Development (FR) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016097626-A1 | NOVEL COMPOUNDS, SYNTHESIS METHOD THEREOF AND USE OF SAME IN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342040-A1 | NOVEL COMPOUNDS, SYNTHESIS METHOD THEREOF AND USE OF SAME IN MEDICINE AND IN COSMETICS | RARA, RARB, RARG | PTGDR 365/4885PTGDR2 225/4885RARB 2/4885 |
| US-10647688-B2 | Compounds, synthesis method thereof and use of same in medicine and in cosmetics | RARA, RARB, RARG | PTGDR 300/4885PTGDR2 224/4885RARB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.